Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD — L1 — Targeted Epigenetic Immune — Modulating Antibody Conjugate
For best results when printing this announcement, please click on link below: Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) (SSE: 688321) today announced that NW001, a fi